We are meaningfully improving every aspect of women's health


Detect earlier. Diagnose easier. Treat better. For all women.

From end-to-never-end.

About Us

We are a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency. Our mission is as important as it is blunt: To radically improve the detection, diagnosis and treatment of women’s health-related disease. We will create an end-to-never-end community for women around the world because we are in this together.


These words from Margaret Mead guide us:


"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has."

About Us

We are a woman-led biotechnology company and we're using data, tech, science and personal experience to shatter complacency. Our mission is as important as it is blunt: To radically improve the detection, diagnosis and treatment of women’s health-related disease. We will create an end-to-never-end community for women around the world because we are in this together.


These words from Margaret Mead guide us:


"Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it's the only thing that ever has."

Real Talk

There's so much more to our well-being than survival. It's about being ourselves. It's about thriving and empowerment. 


We want more information, more sharing.

And we don’t want to be beholden to an old process--we want to be part of creating a new process. We want to stop focusing on remission as a benchmark for success. Because we know that the battle never ends.


We want to make things better. Detect earlier, diagnose easier, treat better. We want to be unreasonable about it. We want to stop accepting things for what they are and work to make them what they should be. 


We will close the gap between science and support. Care, we believe should be more than end-to-end. It should come from an end-to-never-end community. 


We want to talk about the fear, the anxiety, the depression, the marital challenges, the body-shame issues. No. We don't just want to talk about those things. We want to do something about them. 


That’s what we’re building. Together. With you. And nobody will stand in our way. We never doubt that a small group of thoughtful, committed citizens can change the world. 


We are those people.

Detect earlier.

The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA. 


Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection.

Real Talk

There's so much more to our well-being than survival. It's about being ourselves. It's about thriving and empowerment. 


We want more information, more sharing. And we don’t want to be beholden to an old process--we want to be part of creating a new process. 


We want to stop focusing on remission as a benchmark for success. Because we know that the battle never ends.


We want to make things better. Detect earlier, diagnose easier, treat better. We want to be unreasonable about it. We want to stop accepting things for what they are and work to make them what they should be.

We will close the gap between science and support. Care, we believe should be more than end-to-end. It should come from an end-to-never-end community. 


We want to talk about the fear, the anxiety, the depression, the marital challenges, the body-shame issues. No. We don't just want to talk about those things. We want to do something about them. 


That’s what we’re building. Together. With you. And nobody will stand in our way. We never doubt that a small group of thoughtful, committed citizens can change the world. 


We are those people.

Detect earlier.

The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA. 


Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection.

Diagnose easier.

Mammogen’s technology is focused on developing and commercializing multi-gene expression signatures that measure novel circulating messenger RNA (mRNA) biomarkers that are measurable from nearly all biofluids, like blood and saliva.

Diagnose easier.

Mammogen’s technology is focused on developing and commercializing multi-gene expression signatures that measure novel circulating messenger RNA (mRNA) biomarkers that are measurable from nearly all biofluids, like blood and saliva.

Treat better.

While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer. 


This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.



And now we can.

Treat better.

While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer. 


This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.



And now we can.

For all women.

Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.

For all women.

Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.

From end-to-never-end.

We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do. 


RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here. 


We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.

From end-to-never-end.

We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do. 


RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here. 


We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.

Detect earlier.

The path to earlier intervention is cleared by earlier information. That information lives inside of our bodies and is reflected in changes in the expression of our RNA. 


Those changes occur from the moment a disease like cancer takes root in our body and are the key to early detection. 

Diagnose easier.

Mammogen’s technology is focused on developing and commercializing multi-gene expression signatures that measure novel circulating messenger RNA (mRNA) biomarkers that are measurable from nearly all biofluids, like blood and saliva. 

Treat better.

While measurement of circulating tumor DNA (ctDNA) biomarkers has proven to be clinically useful for predicting treatment response, it's failed to help us make meaningful progress towards early detection and diagnosis of complex diseases like cancer. 


This is likely because ctDNA is the product of necrosis, which means that these DNA biomarkers are shed by cancer cells that are already dying. As such, they are telling us about the past. What we really need to understand is the NOW of the disease process.



And now we can. 

For all women.

Transcriptomics, or the measurement of novel gene expression biomarkers, provides the real-time telemetry of the body’s biological response to disease. This means we can get consistent and reliable insights about a patient’s current state. Analyzing a patient's RNA allows us to “listen in” on the language of the cell, while it is alive and active. This could lead to truer, more accurate screening and early--much earlier--detection.

From end-to-never-end.

We don’t require some new, exciting (and expensive) sequencing technology to do what we need to do. 


RNA gene expression can be extracted easily from different biofluids like blood and saliva. It can be reliably, quickly and accurately measured using time-tested and affordable assay technologies at clinical-scale. The technology is already here. 


We're adding the science and the math that makes the difference--the science and the math that will help us improve treatment--and peoples' lives.

The Here and Now

Mammogen’s flagship product is centered around breast cancer. 


Our novel multi-gene expression signature for the non-invasive detection and diagnosis of breast cancer has been extensively validated in blood and saliva testing. It's positioned to unlock regular and reliable screening and diagnostic tools for tens of millions of women--women who are grossly--and unnecessarily--underserved by today's standard of care. 


We're working to eliminate false negatives. That lets us get more women into screening earlier. 


We're working to eliminate false positives so we can safely monitor women with suspicious nodules discovered by imaging.


We're working to do all of this. Regardless of how old you are, where you live, how much money you make, your genetics or your family history. That's our here and now. For you, made possible by all of us.

The Future

We are not stopping. What we're doing is too important.


We are working to develop, validate and commercialize our breakthrough liquid biopsy for breast cancer detection and confirmatory diagnosis. We are exploring other research and development projects, both within breast cancer, and other diseases that affect some-, most-, or only-women. 


When women think about their health-- physical, mental and emotional--and the well-being of those they love, we want them to know that Mammogen, and the Mammogen community, is working with and for them. We want Mammogen to be the first, second and third thing that they think of. 


With you, we want to be part of a thoughtful, committed group of citizens that will change the world. 


Join us.

11 Jan, 2023
Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm
23 Jan, 2022
LONDON, Jan. 19, 2022 /PRNewswire/ -- Liz Cormier-May of Mammogen was named Biotechnology CEO of the Year – USA in the 2021 Global Corporate Excellence Awards.
11 Jan, 2022
Partnership between female-led women’s healthcare companies will give away 50 pairs of Brilliantly Warm wearable bra inserts - the world’s first-ever wearable designed specifically for women after reconstructive surgery - to the breast cancer community
Show More

Non-Invasive detection and diagnosis of breast cancer with Elizabeth Cormier-May

Listen Now
11 Jan, 2023
Elizabeth Cormier-May, CEO of Mammogen, Inc., and Dragonfly Data Ventures, Partner and CCO of IV BioHoldings, joins SGH Corp. board of directors to provide expertise and strategy to the Company’s medical arm
23 Jan, 2022
LONDON, Jan. 19, 2022 /PRNewswire/ -- Liz Cormier-May of Mammogen was named Biotechnology CEO of the Year – USA in the 2021 Global Corporate Excellence Awards.
11 Jan, 2022
Partnership between female-led women’s healthcare companies will give away 50 pairs of Brilliantly Warm wearable bra inserts - the world’s first-ever wearable designed specifically for women after reconstructive surgery - to the breast cancer community
28 Oct, 2021
After recent partnership announcements, female-led women’s health startup, Mammogen, showcases growing list of 2021 awards and recognitions
15 Oct, 2021
Female-led women’s health companies announce comprehensive partnership designed to empower breast cancer community
08 Oct, 2021
About Elizabeth Cormier-May Liz has been in the biotechnology industry for nearly 20 years, with a focus on early start-ups and company creation. She started her career as a medicinal chemist for Novartis Institute for Biomedical Research, working in early discovery oncology. She quickly realized that her ability to create meaningful change in this space was limited, and she pivoted to creating novel markets within diagnostics, where she was able to have greater impact on patients’ quality of care and individualized journey. Liz has spent the majority of her career in oncology and women’s health. She has focused on creating new markets, launching novel products, and building industry-disrupting companies from the ground up. Currently, she is Chairman of the Board, Co-Founder, President and CEO of her digital health start-up, Persona Health, Inc. and CEO and Board Director of an innovative women’s health, diagnostic start-up, Mammogen, Inc. Liz takes a novel approach to both product development and commercialization, always with an eye towards patient empowerment. An entrepreneur at heart, she has found innovative ways to simultaneously add value to her companies’ end-users, as well as her investors. Liz is fueled by the notion that there is a patient, someone’s loved one, at the end of every decision she makes.
08 Oct, 2021
"Woman-led Mammogen Inc. is looking for breast cancers in a whole new way: using liquid biopsy to detect cancers far earlier, for more women, and with greater accuracy than traditional mammograms. They're also passionate about building a community to support women well beyond their initial diagnosis. A special look at the promising future for earlier breast cancer detection, in recognition of Breast Cancer Awareness Month!"
by Eric Kristiansen 22 Sept, 2021
Bio innovation studio behind liquid biopsy companies LiquidLung, HepGene, and Mammogen, comes out of stealth with eight clinical-ready diagnostics Formed to make early detection, diagnosis and treatment of pulmonary, metabolic, and women's health diseases easier and more precise Strikes P4 partnership to unlock market potential for non-invasive lung, liver and breast diagnostics positioned to positively impact 220 million Americans and over one billion globally
by Eric Kristiansen 27 Jul, 2021
Listen to Marty and Liz offer their thoughts and commercial insights into the diagnostics market! Approaching traditional hurdles with innovative solutions is the ONLY way to move the needle forward for our patients!
by Eric Kristiansen 01 Jul, 2021
ALISO VIEJO, Calif, June 30, 2021 /PRNewswire/ -- Mammogen, a female-led women's health startup, has announced the closing of its $2 million series-seed round of equity financing. The round was oversubscribed by a diverse group of high-net-worth investors, comprising 52% women, members of the LGBTQ+ community, and veterans from the US Armed Forces, according to the company.
Show More

To learn more about our programs under development, please send us a note

Contact us

Share by: